• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

磷酸西格列汀联合阿卡波糖治疗老年2型糖尿病患者的效果及安全性研究

张凌毅,李萍华   

  1. 通讯作者,通讯作者
  • 收稿日期:2018-07-19 修回日期:2018-09-26 出版日期:2018-10-25 发布日期:2018-10-25

Efficacy and Safety of Western Gliclazine Combined with Acarbose in the Treatment of Elderly Patients with Type 2 Diabetes Mellitus

Zhang Lingyi and   

  1. Department of Health management section, The Central Hospital of Longhua District,Shenzhen Guangdong,
  • Received:2018-07-19 Revised:2018-09-26 Online:2018-10-25 Published:2018-10-25

摘要: 目的: 探讨磷酸西格列汀联合阿卡波糖治疗老年2型糖尿病的效果及安全性。方法:选取自2016年01月至2017年01月于我院进行治疗的90例2型糖尿病患者(年龄>60岁),依据简单随机化分组方式对90例患者进行随机分组,其中对照组在基础治疗(控制饮食、合理运动等)的基础上给予阿卡波糖治疗。观察组在在基础治疗(控制饮食、合理运动等)基础上给予阿卡波糖联合磷酸西格列汀治疗。比较两组患者血糖以及血脂水平,记录比较两组患者不良反应发生情况。结果:治疗前两组患者血糖相关指标以及血脂水平相接近,组间差异不具有统计学意义(P>0.05)。治疗后两组患者血糖相关指标以及血脂水平均较治疗前有改善,较治疗前差异有统计学意义(P<0.05)。治疗后观察组患者血糖相关指标以及血脂水平改善更为显著,较对照组差异有统计学意义(P<0.05)。两组患者不良反应发生情况无明显差异,组间差异无统计学意义(P>0.05)。结论:老年2型糖尿病患者行磷酸西格列汀联合阿卡波糖治疗,能够有效改善患者血糖以及血脂水平,药物安全性高,临床效果较好。

Abstract: Objective: To explore clinical efficacy and safety of sitagliptin phosphate combind with acarbose in the treatment of type 2 diabetes in the elderly. Methods: From January 2016 to January 2017, 90 patients with type 2 diabetes mellitus were randomly divided into two groups according to simple randomization. The control group was given acarbose treatment on the basis of basic treatment(diet control, reasonable exercise, etc). The observation group was given acarbose combined with Siglidine phosphate on the basis of basic treatment(diet control, reasonable exercise, etc). Blood glucose and blood lipid levels were compared between the two groups, and the occurrence of adverse reactions in two groups were recorded and compared. Results: There was no significant difference in blood glucose index and blood lipid level between the two groups before treatment. There was no significant difference between the two groups(P>0.05). After treatment, the blood glucose index and blood lipid level of the two groups were improved compared with those before treatment, and the difference was statistically significant compared with that before treatment(P<0.05). After treatment, the blood glucose index and blood lipid level of the observation group were improved more significantly than those of the control group(P<0.05). There was no significant difference in adverse reactions between the two groups, and there was no significant difference between the two groups(P>0.05). Conclusion: The elderly type 2 diabetes patients with sitagliptin phosphate combined with acarbose can effectively improve the blood sugar and blood lipid level of the patients, the drug safety is high, and it has important clinical significance.